CIP2A Antibodies

Santa Cruz Biotechnology supplies a comprehensive collection of CIP2A Antibodies for investigating the complex functions of CIP2A protein. CIP2A Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CIP2A, or Cancerous Inhibitor of Protein Phosphatase 2A, plays a critical role in regulating cell growth and survival by inhibiting the activity of protein phosphatase 2A, a key tumor suppressor. Elevated CIP2A expression has been observed across multiple cancer types, highlighting its significance in oncology research. Understanding CIP2A's molecular mechanisms can reveal new possibilities for cancer treatment strategies. Researchers studying CIP2A can gain valuable insights into cellular signaling pathways and their relationship to cancer progression. Advanced research techniques using CIP2A monoclonal antibodies enable detailed analysis of protein interactions and cellular localization patterns. Investigating CIP2A's role in different cancer types may lead to breakthrough discoveries in targeted therapies. Santa Cruz Biotechnology monoclonal antibodies for CIP2A research support scientists worldwide in advancing our understanding of cancer biology and developing innovative therapeutic approaches.